Immuno-Biological Laboratories Co Ltd
TSE:4570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (5.2), the stock would be worth ¥579.88 (57% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12 | ¥1 334 |
0%
|
| 3-Year Average | 5.2 | ¥579.88 |
-57%
|
| 5-Year Average | 5.3 | ¥583.04 |
-56%
|
| Industry Average | 2 | ¥218.78 |
-84%
|
| Country Average | 1.1 | ¥121.88 |
-91%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
12.4B JPY | 12 | 34.1 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 327.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 3.9 | 26 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 5.1 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 7.2 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | 5 | -119.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.6 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 9.6 | 47.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 1.7 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 6.5 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 1.1 |
| 70th Percentile | 1.9 |
| Max | 12 107 466 |
Other Multiples
Immuno-Biological Laboratories Co Ltd
Glance View
Immuno-Biological Laboratories Co., Ltd. engages in the manufacture and sale of antibody-related reagents and pharmaceutical products. The company is headquartered in Fujioka-Shi, Gumma-Ken(Gunma-Ken) and currently employs 65 full-time employees. The company went IPO on 2007-03-02. The firm operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
